{'52WeekChange': 0.17785633,
 'SandP52WeekChange': 0.0644362,
 'address1': '1100 Winter Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 10.48,
 'askSize': 800,
 'averageDailyVolume10Day': 607562,
 'averageVolume': 567998,
 'averageVolume10days': 607562,
 'beta': 0.95014,
 'beta3Year': None,
 'bid': 10.01,
 'bidSize': 1200,
 'bookValue': 7.697,
 'category': None,
 'circulatingSupply': None,
 'city': 'Waltham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 10.64,
 'dayLow': 9.78,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.375,
 'enterpriseToRevenue': 1.63,
 'enterpriseValue': 522521056,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 649 1654',
 'fiftyDayAverage': 7.9574285,
 'fiftyTwoWeekHigh': 13.53,
 'fiftyTwoWeekLow': 4.41,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16728213,
 'forwardEps': 0.19,
 'forwardPE': 52.63158,
 'fromCurrency': None,
 'fullTimeEmployees': 440,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.01745,
 'heldPercentInstitutions': 1.3431599,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 685843200,
 'lastSplitFactor': '3:2',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/amagpharma.com',
 'longBusinessSummary': 'AMAG Pharmaceuticals, Inc., a pharmaceutical company, '
                        'develops, manufactures, and commercializes '
                        "therapeutics for maternal and women's health, and "
                        'anemia management in the United States. The company '
                        'markets Feraheme (ferumoxytol), an intravenous iron '
                        'replacement therapeutic agent for the treatment of '
                        'iron deficiency anemia in adult patients who have '
                        'intolerance to oral iron or have had unsatisfactory '
                        'response to oral iron, as well as patients who have '
                        'chronic kidney disease; Makena, a hydroxyprogesterone '
                        'caproate injection to reduce the risk of preterm '
                        'birth in women pregnant with a single baby who have a '
                        'history of singleton spontaneous preterm birth; '
                        'Intrarosa(prasterone) vaginal insert steroid for the '
                        'treatment of dyspareunia due to menopause; and '
                        'Vyleesi (bremelanotide), an auto-injector device for '
                        'the treatment of hypoactive sexual desire disorder in '
                        'pre-menopausal women. Its product candidates also '
                        'include AMAG-423 (ovine), an antibody fragment, which '
                        'is in Phase 2b/3a trial for the treatment of severe '
                        'preeclampsia in pregnant women; and Ciraparantag, an '
                        'anticoagulant reversal agent that is in planned Phase '
                        '2b trial for the treatment of novel oral '
                        'anticoagulants or low molecular weight heparin. The '
                        'company sells Feraheme to authorized wholesalers and '
                        'specialty distributors. The company has license '
                        'agreements with Endoceutics, Inc., Palatin '
                        'Technologies, Inc., Velo Bio, LLC, Prasco, LLC, '
                        'Perosphere Pharmaceuticals Inc., and Antares Pharma, '
                        'Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 '
                        'and is headquartered in Waltham, Massachusetts.',
 'longName': 'AMAG Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 342728000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_247782',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -368863008,
 'nextFiscalYearEnd': 1640908800,
 'open': 10.22,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.86,
 'phone': '617 498 3300',
 'previousClose': 10.075,
 'priceHint': 2,
 'priceToBook': 1.2992074,
 'priceToSalesTrailing12Months': 1.0689939,
 'profitMargins': -1.1505101,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 10.64,
 'regularMarketDayLow': 9.78,
 'regularMarketOpen': 10.22,
 'regularMarketPreviousClose': 10.075,
 'regularMarketPrice': 10.22,
 'regularMarketVolume': 938225,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 34272800,
 'sharesPercentSharesOut': 0.35950002,
 'sharesShort': 12321041,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 12355253,
 'shortName': 'AMAG Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.7554,
 'shortRatio': 20.17,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'AMAG',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -10.871,
 'twoHundredDayAverage': 8.140791,
 'volume': 938225,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.amagpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02451'}